PHILADELPHIA— Multiple prior studies have found higher levels of inflammation in older individuals with depression. Now, a new Penn Medicine study has found that clinically depressed older individuals, on average, don’t have elevated levels of inflammation if they don’t already have other inflammatory conditions such as arthritis.
The new study, published recently in Nature Translational Psychiatry, suggests that depression occurs independently of inflammation for many older adults. Furthermore, depression-inflammation links are due to the greater incidence of inflammatory conditions, which in general are common in older people.
“It is still true that inflammatory illnesses can contribute to depression, but our findings suggest that there is a subset of individuals with late-life depression who do not have elevated levels of inflammation,” said study senior author Yvette Sheline, MD, McLure Professor of Psychiatry and Behavioral Research in the Perelman School of Medicine at the University of Pennsylvania.
Yvette Sheline, MD
National surveys in the United States suggest that, although depression is diagnosed more often among younger adults, about five percent of people who are at least 50 years old have had a major depressive episode in the past year. Researchers suspect that many of these cases of late-life depression are caused by inflammation—in part because studies have found higher levels of inflammatory immune proteins in the blood of older people with depression, compared to non-depressed people of the same age.
Prior research also has shown that levels of inflammation markers generally tend to rise with increased age, as chronic illnesses set in and the body’s immune-regulating systems weaken. Based on such findings, doctors have tested anti-inflammatory drugs in patients with depression, and have found that they can improve outcomes when added to standard anti-depressant therapy.
The new study reveals, however, that the link between depression and inflammation is not as clear-cut as the prior literature suggests. Sheline and colleagues used online and in-person screening of over 1,100 depressed individuals to recruit a group of 63 individuals, age 50 to 80, who met criteria for major depressive disorder but did not have other inflammatory conditions. Comparing this group to 29 healthy individuals of the same age, even with highly sensitive measurements, the researchers found no significant differences in bloodstream levels of 29 different inflammation-linked immune proteins.
The researchers then randomized 60 of the depressed patients to receive either a standard antidepressant drug, or the antidepressant plus an anti-inflammatory drug, or placebo, for eight weeks. They found that while the two antidepressant-treated groups showed significant improvement in their depression ratings relative to placebo, there was no significant difference in outcome between the antidepressant and the antidepressant-plus-anti-inflammatory group. Moreover, in all three groups, the subjects’ blood levels of inflammatory markers were low before treatment and did not drop significantly as a result of treatment. The researchers even tested the cerebrospinal fluid of the subjects for levels of the inflammatory protein IL-1β, and again found low levels both before and after treatment.
The study therefore suggests that, in many older adults, depression occurs independently of inflammation, and probably won’t be alleviated by anti-inflammatory treatments unless inflammation is present in addition to depression.
The researchers note, however, that because their study excluded late-life depression patients who have inflammatory disorders, it leaves open the possibility that inflammation from such disorders can contribute to depression.
“Our study supports the view that depression consists of different sub-categories, some with inflammation and some without,” said Sheline, who is also director of Penn’s Center for Neuromodulation in Depression and Stress. “People who have depression should consult with their doctor to see if they have other illnesses that could cause inflammation, since there is evidence that increased inflammation can cause depressive symptoms.”
Additional co-authors include Eline Luning Prak, Thomas Brooks, Walid Makhoul, Joanne Beer, Ling Zhao, Tommaso Girelli, and Carsten Skarke.
The study was funded by the National Institute of Mental Health (R01 MH098260-02). Inflammatory biomarker assays were performed in the Penn Human Immunology Core facility.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $9.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 52,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.